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Traditional allogeneic bone marrow transplan-tation, introduced primarily for correction of irreversible aplasia whether congenital1 or ac-
quired2 may also be life saving in other defects exem-
plified by immunodeficiency disorders3 and metabolic 
diseases.4 It is currently accepted as having a place in 
treating acute5 and chronic leukemia,6 Hodgkin7 or in-
dolent8 as well as aggressive lymphoma9 in addition to 
myeloma.10 The scope increasingly extends to a number 
of solid tumours amongst which are breast cancer11 and, 
in selected cases, acquired lesions including paroxysmal 
nocturnal haemoglobinuria12 or myeloproliferative syn-
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BACKGROUND AND OBJECTIVES: immunohematopoietic stem cell transplantation has curative potential in 
selected hematologic disorders. stem cell transplantation was introduced into south africa in 1970 as a struc-
tured experimental and clinical program. in this report, we summarize the demography and outcome by disease 
category, gender, and type of procedure in patients older than 18 years of age who were seen from april 1995 
to december 2002.
PATIENTS AND METHODS: this retrospective analysis included 247 individuals over 18 years of age for whom 
complete data were available. these patients received grafts mostly from peripheral blood with the appropriate 
stem cell population recovered by apheresis. 
RESULTS: patient ages ranged from 20 to 65 years with a median age of 42 years. there were 101 females and 
146 males. there were no withdrawals and 63% survived to the end of the study. at 96 months of follow-up, 
a stable plateau was reached for each disease category. median survival was 3.3 years (n=6, 14.6%) for acute 
lymphoblastic anemia, 3.1 years (n=44, 18%) for acute myeloid leukemia, 2.8 years (n=47, 19%) for chronic 
granulocytic leukemia, 2.8 years (n=71, 29%) for lymphoma, 1.5 years (n=23, 9%) for myeloma, 1.43 years 
(n=10, 4%) for aplasia, and 1.4 years (n=38, 15%) for a miscellaneous group comprising less than 10 examples 
each. multivariate analysis showed that only diagnosis and age had a significant impact on survival, but these 
two variables might be interrelated. there was no significant difference in outcome by source of graft. 
CONCLUSION: the results confirm that procedures carried out in a properly constituted and dedicated unit, 
which meets established criteria and strictly observes treatment protocols, generate results comparable to those in 
a first World referral center. low rates of transplant-related mortality, rejection and graft-versus-host disease are 
confirmed, but the benefits cannot be extrapolated outside of academically oriented and supervised facilities. 
dromes amongst which is idiopathic myelofibrosis.13
Outcome continues to benefit from more precise 
matching at both major14 and minor15 histocompatibility 
loci, using DNA-based or molecular techniques, which 
also make possible definition of chimerism16 or quanti-
tation of minimal residual disease.17 Nevertheless prob-
lems persist amongst which are rejection18 and acute19 
or chronic graft-versus-host disease.20 These are offset 
by better utilisation of immunosuppressive regimens 
for conditioning21 as well as in the post-procedure pe-
riod with corticosteroids, methotrexate,22 cyclosporin,23 
tacrolimus24 and mycophenolate mofetil.25 Concurrently 
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there is greater attention being given to supportive care,26 
proactive evaluation and maintenance of nutrition un-
derpinned by strong psychosocial networks.27 
Against such a background this therapeutic option 
was introduced into South Africa in 1970 via an animal 
allograft program28,29 with active research and ongoing 
clinical development sustained by the original interna-
tionally designated team. On this basis it has been pos-
sible to provide a forty-year perspective in which four 
separate developmental, albeit overlapping, periods can 
be identified with the appreciation that such distinction 
is somewhat artificial.30 
Firstly was a need to pioneer the use of apheresis in 
this country so replacing the obsolete delivery of blood 
products in bottles and, applied initially, to explore a 
place for granulocyte transfusions.31 There was subse-
quent permeation of the technology into commercial 
blood banks where, in the course of the last 30 years, it 
has entirely appropriately become a well-established rou-
tine. Concomitantly to expand the use in processing bone 
marrow after collection whilst, latterly, to directly harvest 
the corresponding population after mobilisation with 
stimulatory peptides into the peripheral blood.32 The lat-
ter resulted in a substantially shortened time to engraft-
ment,33 a low incidence of relapse in acute myeloid leuke-
mia, but reappearance of cytomegaloviral infections.34 
Secondly were preliminary cooperative studies 
with Jeanne Borel at Sandoz in Basle showing that 
cyclosporin A, at least in experimental animals, de-
creased both the incidence and severity of acute graft-
versus-host disease. Follow-up in the clinic, however, 
revealed that while these benefits could be reproduced 
in patients, prevention was only partial and did not 
abrogate recurrence.35 
Thirdly there followed collaborative research initially 
in Cambridge36 and with the same group continuing 
these investigations latterly in Oxford37 that defined a 
role for T-lymphocyte depletion using Campath mono-
clonal antibodies in vitro by adding them to the graft in-
the-bag.38 One consequence was recognition of an altered 
expression or forme fruste of immunologically mediated 
acute graft-versus-host disease that appeared later, was 
typically limited to skin and usually responsive to topi-
cal steroids although on occasions systemic administra-
tion was unavoidable.39 This syndrome is not considered 
chronic in the accepted sense either to time of onset or 
more importantly having a quite different clinical spec-
trum and remains distinct being conceptually regarded as 
reflecting modulation by the antibody used in this partic-
ular way. Such an approach remains firmly established as 
local, and much wider, practice.40 It also forms part of the 
broader ongoing participation and reporting of results to 
the Campath users group.41 The original lytic IgM pro-
tein was subsequently replaced by an opsonic equivalent 
and more recently shift to a chimeric humanised version 
designated Campath 1H.42 In all these studies engraft-
ment remains uniform and rejection infrequent. This ap-
plies even when extended to include family members and 
matched unrelated volunteer donors identified through 
the South African Bone Marrow Registry43 interacting 
with corresponding European Centers and the American 
National Donor Program44.
Fourthly, appreciating that peer review was crucial 
to maintaining standards, but unfortunately non-exis-
tent in this country or anywhere in sub-Saharan Africa, 
every patient, from inception, has been reported to 
the International and then Autologous Bone Marrow 
Transplant Registries for scrutiny and audit. After more 
than twenty years of refinement and consolidation, our 
original program was transferred, in 1995, to an aca-
demic Department in the private sector. Maintenance 
of this active surveillance mechanism, now to the Center 
for International Blood and Bone Marrow Transplant 
Research, has sustained unbroken reaccreditation to 
the present time. Concurrently the original group re-
main designated as a Transplant, Harvest and Donor 
Center within European Bone Marrow Transplant 
Registry and concurrently with participation and ap-
proval for transplantation as well and as harvesting by 
the American National Donor Program.44
After 30 years it is appropriate that this single team 
experience be updated to allow comparison, particularly 
in the last decade, to other private and state services in 
this country, but, more critically, to be measured against 
results on a worldwide basis. 
It is mandatory in South Africa, as in other emerg-
ing, developing or under-resourced areas, that a clear 
and reliable statement of what can be expected is avail-
able. Such statistically analysed data provides perspec-
tive against which to evaluate changes that continue to 
occur as a result of the ever-shifting stance of managed 
health care providers for insured patients. This is espe-
cially relevant as government starts to focus on costs 
in private hospitals whilst medical aids seek to define 
preferred providers, not as one would expect on cost-
effective benefits, but primarily using financial or in-
centive - driven criteria. Scientifically, academically and 
intellectually, it is argued that such monetary focus is 
inappropriate and should defer to the identification of 
high-performing multidisciplinary units that can meet 
the requirements for the widely acknowledged center ef-
fects.45,46 Corresponding information for those under 
18 years of age is the subject of a separate publication.47 
To definitely document the introduction and subse-
original research report CaPe TOwN
Hematol Oncol Stem Cell Ther 2(2) Second Quarter 2009 hemoncstem.edmgr.com322
quent development the comprehensive experience in 
this country has recently been reviewed.48 
Also the wider place of these interventions from 
introduction at the University of Cape Town and 
Groote Schuur Hospital in 1970 with establishment 
in the private sector with continued development over 
the last 15 years is in preparation for the History of 
Medicine Series.49
Accordingly, we detail, from this academic unit in 
Cape Town, statistically analysed results and define pro-
jected basic as well as clinical research that will focus on 
immunologic reconstitution.50 The latter is anticipated 
to correlate laboratory findings with patient response to 
viral, parasitic and bacterial infections in the context of 
reverse isolation and emerging multi-drug resistance.51 
The particular relevance is that this program will explore 
immunosuppression by only ex vivo T-cell depletion 
that is distinctly different from many more conventional 
approaches where a range of agents are administered for 
periods of time after engraftment for control of rejec-
tion and graft versus host disease. Additionally, to bet-
ter document commitment to quality-of-life assessment 
with psychosocial counselling in conjunction with liai-
son psychiatry. There already emerges a strong argument 
to restrict these costly treatments to active teams that 
have a clear record of meeting first world performance 
judged by published outcome, attract sufficient volume 
to sustain the advantages of the well-recognised center-
effect52,53 and, in developing or under-resourced areas, 
meet criteria for international acceptance via endorse-
ment as full participating membership in appropriate 
registries.54 Indeed it has recently been proposed that 
these activities be collected and analysed by establish-
ing a repository within the South African Bone Marrow 
Registry to match the ongoing survey by European Bone 
Marrow Transplant Group.55 The latter focuses on cord 
blood but draws attention to the widely recognised argu-
ment to require reporting of all procedures whilst leaving 
the way open for local groups to assign resources region-
ally. These are not exclusive but can readily be revised to 
include survival analysis in the future.
PATIENTS 
Three hundred and twenty  Consecutive individuals, 
over 18 years of age, eligible for immunohaematopoi-
etic stem cell transplantation were registered from April 
1995 to December 2002, a number of which were in-
cluded in a recent audit by the Center for International 
Blood and Marrow Transplant Research and retrospec-
tively analysed. After the data was cleaned to implement 
age restriction a total of 247 cases qualified as the basis 
for this report. 
METHODS 
Diagnosis 
Following comprehensive clinical assessment agreed 
definitions were used for aplasia,1 acute5 and chronic6 
leukemia, Hodgkin7 or other lymphomas9 and myelo-
ma.10 Morphologic features on bone marrow aspiration 
were supplemented by appropriate cytochemistry,56 
flow cytometry,57 karyotyping and molecular genetics 
documented.58 Immunohistochemistry was used as 
necessary on tissue and trephine biopsies.59 
Radiology 
Conventional films were complemented by computer-
ized axial tomography including determination of bone 
mineral density.60 Skeletal involvement was recorded 
and changes graded according to locally developed cri-
teria (unpublished). The preferred PET-CT was not 
routinely available during this time.
Biochemistry
Renal and hepatic profiles, serum protein electropho-
resis, immunoglobulin quantitation and markers of tu-
mour activity included sensitive C-reactive protein and 
ß2 microglobulin.
Staging
Where relevant this was according to the Cotswold 
modification of the Rye system or, preferably, the inter-
national prognostic index.61
Pre-transplant phase 
Physical facility
Management was in reverse isolation where each two-
roomed suite had dedicated shower and toilet. There 
was a particular focus on patient information and in-
teractive counselling offered to help maintain optimum 
quality of life.62-64 In addition details of local bone mar-
row transplant unit was provided in two specially writ-
ten information brochures.65,66
Nutritional status 
Selective decontamination of the bowel relied on oral 
levofloxacin.67 A low microbial diet was provided with 
daily review of weight, caloric status and vitamin as well 
as trace metal balance.68 All patients were in the routine 
care of a trained academic dietician.
Where targets were not achieved placement of a na-
sojejunal, as opposed to nasogastric, fine bore feeding 
tubing was used and this remains a subject of evaluation 
(Wood, Schloss, O’Keefe, Jacobs - study in progress). 
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Total parenteral nutrition was infrequently needed and 
then largely in the paediatric age group.
Nausea and vomiting
These symptoms were anticipated and recipients re-
ceived 72 hours of oral phenobarbitone, metoclo-
pramide or serotonin antagonists prior to admission. 
This was switched to intravenous route at the time of 
conditioning and dosage titrated to proactively pre-
vent such side effects with this regimen supplemented 
by paracetamol, dexamethasone or valoid orally or by 
suppository as needed. More recently neurokinin-1 
antagonists and second-generation 5-hydroxytryp-
tamine antagonist69,70 have become available and, 
together with motility-controlling drugs, were used 
when indicated.71 Clostridium difficile was treated 
with oral metronidazole or, if resistant, vancomycin by 
the same route.72
Neutropenic fever and viral infections
Pyrexia, defined as 38°C, when confirmed at 60 min-
utes, required repeated cultures of blood, urine and 
stool followed by empiric single agent ceftazidime73 or 
tazocin74 with the beta-lactams given as 24-hour con-
tinuous intravenous infusion. Isolation of pathogens 
was the basis of switching to in vitro sensitivity directed 
regimens and typically with 2 drugs synergistic in vitro 
for persisting fever. 
Culture-negative cases were managed with 1 mg/kg 
of amphotericin in 200 ml 5% dextrose water given, as a 
continuous 24-hour infusion since side effects, and par-
ticularly nephrotoxicity, were abrogated.75
Cytomegalovirus was monitored by serology and 
more recently routinely screened for by the PP65 and 
PP67 assay with polymerase chain reaction when leu-
kocyte counts were below 1×109/L. Pre-emptive treat-
ment was by intravenous gancyclovir76 or valganciclo-
vir77 and switched to the latter agent orally for a further 
two weeks once the virus was no longer detectable. It is 
notable that, at least in solid organ transplants related 
to the pharmacokinetics78 and pharmacodynamics,79 
both agents can result in drop in white count and delay 
recovery in neutrophil and monocyte levels.80,81
Transfusion policy 
Neutropenia, particularly when associated with fever, 
of less than 0.5×109/L granulocytes received 300g 
GCSF intravenously until this level was stable above 
1×109/L and temperature again normal.82,83 Packed 
red cells were administered on a standard regimen 
for symptom-relief with haemoglobin arbitrarily kept 
above 100 g/L.84 Platelets were used in those at risk 
from bleeding to maintain counts greater than 30×109/
L with single-donor apheresis units85,86 concurrently 
with 500 mg of cyklokapron orally or intravenously 
every 8 hours.87 These were collected initially from a 
dedicated volunteer panel88 and with quality control to 
meet safety standards.89 
Surveillance
Data analysis was on a moment-to-moment basis. All 
decisions were updated daily at morning report and in-
cluded planning for nutrition, psychosocial counselling, 
liaison psychiatry, physiotherapy with review of medi-
cation by haematology pharmacists. 
Central venous access 
This was secured using a double-lumen Brovic cath-
eter inserted under general anaesthetic following the 
Hickman technique.90 The position was checked on 
recovery to confirm that return of muscle tone did 
not dislocate the tip, ideally positioned 1 cm above 
the junction of the superior vena cava with the right 
atrium.91 Low dose warfarin, with the INR in the nor-
mal range, was employed to reduce the risk of venous 
thromboembolism.92 
Counselling and liaison psychiatry 
At diagnosis a family conference was convened that in-
cluded introduction to nursing and paramedical staff, 
dietician and physiotherapist. Previous cytotoxic drug 
treatment and irradiation was documented and the 
risks, as well as potential benefits, of the procedure 
explained and brochures describing the organisation 
of the department and the unit provided. Once all is-
sues had been fully discussed the informed consent was 
signed by patient or, in the case of minors, by parents or 
responsible guardians. 
Prior treatment protocols
Donor selection 
Histocompatibility was confirmed by standard meth-
ods93 via the South African Bone Marrow Registry43 
where appropriate searches extended to include British, 
Australian, Dutch and American participating cen-
ters: further consultation was with the Leiden Group. 
These activities were part of a worldwide research 
project with certification through the International 
Immunogenetics Group.94
Acute lymphoblastic leukemia (n=14: 6%) 
Treatment was standardised to the Berlin-Frankfurt-
Munster or BFM programs.95,96
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Acute myeloid leukemia (n=44: 18%) 
Initially the combination of cytosine arabinoside, an an-
thracycline antibiotic with an epipodophyllotoxin97,98 
was used. More recently this was extended to the British 
Medical Research Council AML 15 program. In some 
instances managed health care organisations, on advice of 
their local consultants, have unfortunately restricted access 
to these regimens despite clear evidence of benefit from 
adding gemtuzumib ozogamicin to this drug regimen.99
Chronic granulocytic leukemia (n=47: 19%)
Disease control was rapidly achieved using hydroxyurea 
and latterly imatinib mesylate.100 Transplantation was 
offered to fully matched recipients particularly with the 
escape from the tyrosine kinase, if cytogenetic abnor-
malities developed or this was patient’s choice.101
Hodgkin and other lymphomas (n=71: 29%) 
Current protocols parallel those used by the European 
Organization for Research and Treatment in 
Cancer102,103 or the German Hodgkin and Lymphoma 
Study Group.104,105 
Myeloma (n=23: 9%) 
Stratification was by comorbidity106 and risk factors 
using guidelines from the International Myeloma 
Working Group.107 VECD comprising vincristine, epi-
rubicin, cyclophosphamide and dexamethasone108 were 
preferred. Here the target was greater than seventy-five 
percent reduction in both paraprotein level and plasma 
cell infiltrate of marrow trephine biopsy to qualify for 
autologous immunohaematopoietic stem cell grafting. 
Thalidomide was not approved by local Third Party 
funders during these studies. In appropriate cases main-
tenance depended on negotiating for this agent with 
bortezomib still not being available. Alternatives were 
pulsed melphalan and methylprednisolone or salvage 
with dexamethasone and vinorelbine.
Aplasia (n=10: 4%) 
Intensive support included limiting blood and other 
components as far as possible. Where suitable sibling 
donors were available this remained the preferred treat-
ment. In other instances immunosuppressive regimens 
including high dose methylprednisolone and antilym-
phocyte globulin were standard.109-111 
In keeping with established practice, including this 
country, irreversible bone marrow failure was a prime 
indication for one or other form of immunohaemato-
poietic stem cell allografting either matched sibling, un-
related or minimally mismatched family donors.
Miscellaneous group (n=38: 15%) 
This varied by subtype. In hairy cell leukemia 2-chloro-
deoxyadenosine112 was largely successful and so seldom 
needed grafting. Cutaneous lymphomas, including my-
cosis fungoides or Sezary syndrome, received appropri-
ate superficial irradiation.113,114 Gemcitabine115 or alem-
tuzumab116 for tumours of T-lineage and individualised 
therapy in B-lymphocyte neoplasms appropriate for risk 
category.117 Individuals received pulsed chlorambucil or 
combinations of rituximab, fludarabine and cyclophos-
phamide: latterly the anti-CD52 monoclonal antibody 
Campath or alemtuzumab.118 In selected refractory in-
stances allografting was an option.119
Special projects 
A number of prospective investigations are actively eval-
uating changes in pulmonary,120,121 skeletal,122,123 gastro-
intestinal,124-126 renal127 and cardiovascular status128,129 
as an integral part of management and incurred no new 
costs. Immunologic reconstitution130,131 is to become a 
major focus of the program to explore the importance of 
side effects better now described as survivorship.132,133
Transplantation phase: conditioning regimens
Two myeloablative options were used. In none of these 
patients was this primarily immunosuppressive-alter-
natively described as reduced intensity. 
Radiotherapy 
12 gray fractionated whole body irradiation on days 
-7-6-5 is followed by 60 mg/kg of cyclophosphamide 
intravenously on days -4 and -3, and 6 gray fractionated 
total nodal irradiation on days -2 and -1. The graft is 
infused on day 0.
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Chemotherapy
Busulphan combined with cyclophosphamide, used 
originally in the four-day regimen has been replaced 
by two-day alternative: the former being intravenous 
as opposed to oral.134,135 In selected individuals, where 
this agent was contraindicated, fludarabine was used. 
Additionally in over eighty percent of our cases the first 
choice was the BEAM preparative regimen.136 
Re-transplantation 
With primary or secondary graft failure preparation 
was with fludarabine137 antilymphocyte globulin and 
cyclophosphamide.138
Mobilization and quality control
Granulocyte-colony stimulating factor was com-
menced subcutaneously on Day 5 at a flat dose 
of 300µg with the last injection at 04h00 on the 
day of first large volume apheresis harvest. CD34 
population were noted but not specifically used 
to time these collections.32
Autografts
Cyropreservation was undertaken as previously de-
scribed.139
Allogeneic transplants 
Histocompatible siblings received only the ex vivo 
T-cell depleted product after exposure to Campath 
1H in-the-bag.38 Alternative family members and 
matched unrelated volunteer donors - exclusively - 
received cyclosporin at full therapeutic dose for six 
months with a fifty percent reduction at three months 
and the remaining three months at twenty five per-
cent optimum dose. 
Infusion techniques
Premedication, given half an hour before the graft 
containing the monoclonal antibody, consisted of 100 
mg of hydrocortisone, 12.5 mg of promethazine hy-
drochloride intravenously and 500 mg paracetamol 
orally. Continuing non-invasive cardiovascular and 
respiratory monitoring was sustained until vital signs 
were stable. Oxygen desaturation necessitated rate 
adjustment of this infusion and this occurred in less 
than five percent of the procedures. In approximately 
thirty percent pyrogenic reactions with abdominal dis-
comfort were attributed to the immunoglobulin. There 
were no lasting side effects. In autografts transient fe-
ver was initially attributed to presence of DMSO and 
recently ascribed to contaminating granulocytes in the 
apheresis product.140
Product manipulation
Bone marrow, although no longer routinely used, con-
tinued to accommodate matched unrelated volunteer 
programs predicated on requirements of the collabo-
rating center from different parts of the world. Here 
the harvest was modified using the standard apheresis 
technology: vide supra:139 once greater than ninety-five 
percent of the mononuclear cells have been recovered 
the residual blood was reinfused to the donor or dis-
carded. The immunohaematopoietic stem and progeni-
tor concentrate had the standard ex vivo addition of 20 
mg of Campath 1H, incubated at 37° for half an hour 
and infused.38
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Peripheral blood collections required a minimum 
number of 6.5×108/kg mononuclears and preferably 
greater than 2×106/kg CD34 positive population. 
Long term colony initiating cells were determined 
in clonogenic assay.141,142 It was noted that, whilst 
remaining standard, there is evidence that this par-
ticular approach may not optimally predict outcome 
especially in cord-derived grafts.143 Specifically in 
only four patients who failed to meet this criteria 
there was, nevertheless, rapid reconstitution of nor-
mal values.
Pain management 
This was according to World Health Organization 
guidelines.144
Post-transplant surveillance
Immunosuppression was not used in histocompatible 
siblings. Conversely, in family members and matched 
unrelated donors, the recipients received cyclosporin 
maintaining therapeutic levels of 1500 ng/mL on the C2 
assay:145 the dose was cut to fifty percent at six months, 
twenty five percent at nine months and discontinued at 
twelve months protocol included 200 mL of stabilised 
human serum weekly146 in addition to 500 mg of valaci-
clovir twice daily for viral prophylaxis for three months 
and co-trimoxazole comprising trimethoprim 80 mg 
and co-trimoxazole 400 mg daily for one year.147,148
Statistical analysis
Data was examined using the Kaplan-Meier product 
limited estimator, Cox proportional hazard based on 
initially fitting each risk factor, multivariate analysis and 
Pearson Chi squared contingency tables for indepen-
dence testing.149,150
RESULTS
Age and gender
Median and mean age were both 42 years with a range 
from 19.45 to 65.0 (Figure 1). At transplantation, 
mean age for females was 41.3 years and that for males 
42.7 years. Most were between 40 and 50 years with a 
much-reduced number between 60 and 70. There were 
101 female and 146 males. Gender was balanced in the 
middle but at the other end of the spectrum roughly 
double the number of males were present. Survival 
decreased with age (Figure 2) but despite difference 
between the groups, it is notable that the estimate of 
survival function is roughly the same. This suggests 
that once the initial transplant-related mortality is past, 
there is equal benefit from the procedure. There are no 
gender differences evident (Figure 3).
Influence of transplantation procedure
When subdivided by those having peripheral blood 
stem cell autologous or allogeneic transplants and fur-
ther into groups were the graft source was from bone 
marrow or peripheral blood treated respectively with 
the of opsonic monoclonal antibody Campath IG or 
the humanised variant designated IH survival ap-
pears unaffected by the immunoglobulin (Figure 4). 
There was no statistical difference between control pa-
tients receiving peripheral blood stem cell autografts 
(n=101) when ex vivo t-cell depletion is carried out 
with the Compath IG bone marrow (n=14) or blood 
(n=36). Similarly, when humanized monoclonal an-
tibody IH was used in-the-bag on the mononuclear 
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Figure 6. Outcome by diagnosis.
cells drived by apheresis from the circulation (n=96) 
outcome was comparable.
Outcome by diagnosis
The majority of the patients were referred with non-
Hodgkin lymphoma followed by chronic granulocytic 
and then acute myeloid leukemia (Figure 5). 
Analysis of survival on this basis (Figure 6) (Table 
1) shows substantial differences with superiority for the 
acute leukemias followed by lymphoma although these 
are not stratified for Hodgkin and other variants with 
approximately equal outcome for the remaining cases 
with aplasia and myeloma.
Cause of death
The majority were multifactorial having a final 
common pathway of severe inflammatory response 
syndrome151 culminating in multiple organ dysfunc-
tion.152 Where separation and assignment to particu-
lar predominant explanation was possible, relapse, 
followed by respiratory failure accounted for most 
of the remainder with small numbers probably arti-
ficially attributed to septicaemia and cerebral events 
(Figure 7).
DISCUSSION
The introduction initially as conventional transplanta-
tion of bone marrow and subsequent development in 
South Africa over the ensuing 35 years48 has, in the last 
decade, started to raise questions about sustainabil-
ity of these often life saving, albeit costly, endeavours. 
Unquestionably they require a substantial investment 
of resources in providing tertiary or even quaternary 
level physical facilities originally based in state sup-
ported University teaching units but increasingly re-de-
ployed at privately funded hospitals or clinics. Both ar-
eas depend for continued effective function on retaining 
a stable complement of highly trained and experienced 
doctors with nurses as well as paramedicals that make 
up the indispensable multidisciplinary team. Here aris-
es the first problem, and it is as acute as serious, with 
severe understaffing becoming ever more critical at 
all levels reflecting a steadily accelerating exodus from 
South Africa of these professionals. Secondly, in mon-
etary terms, there is inevitable competition with other 
health care priorities most strikingly in sub-Sahara by 
those created in the wake of an escalating acquired im-
munodeficiency disease pandemic.
Sharp focus is given to these sobering realities by an 
analysis describing such activities in Europe153 coupled 
with a recent survey for the first time documenting the 
current local situation.30 Accordingly the time was judged 
appropriate to set out the way in which the latter point 
had been reached154 with a further intention of offering 
perspective for the future of immunohaematopoietic stem 
cell grafting in a Third World country seeking to objec-
tively balance need against capacity. Such a repository has 
a number of potential benefits. It will allow government 
or other licensing authorities to look at the way regional 
activities are distributed. Secondly to ensure equitable ac-
cessibility to state funded programs and for all centers, 
particularly those in the private sector, to show effective-
ness in adults and children, determined objectively by 
outcome analysis. Such impartiality facilitates scrutiny by 
managed healthcare organisations and medical aids of re-
sults from individual teams and so shifts the responsibil-
Table 1. Survival time in years from diagnosis.
Diagnosis Number Mean Median Minimum Maximum
acute myeloid 
leukemia 44 3.131 3.436 0.025 7.496
acute 
lymphoplastic 
leukemia
14 3.301 2.929 0.814 5.923
Chronic 
myeloid 
leukemia
47 2.81 2.334 0.019 7.726
Lymphoma 71 2.764 3.142 0.011 6.94
Multiple 
myeloma 23 1.543 1.025 0 6.307
aplastic 
anemia 10 1.433 0.697 0.074 5.885
Others 38 1.394 0.781 0.014 5.66
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Stroke
Matched unrelated donor
Multi organ failure
Others
Relapse
Respiratory failure
Septicemia
Transformed
17%
6%
3%
4%
7%
4%
39%
20%
Figure 7. Causes of death.
ity to ensuring that potentially incentive-driven financing 
is replaced by supporting preferred providers where audit 
and accountability take into consideration the all-impor-
tant center effect.
In an endeavour to provide this type of non-partisan 
information consecutive admissions over a seven-year 
period were analysed from an academic center based in 
the private sector. The facility was specifically created to 
recapitulate the standard University style department. 
Interestingly the same investigators that designed and 
commissioned the prototype and custom-built bone 
marrow transplant unit in the Groote Schuur Hospital 
have extended this experience over 35 years.48 
Thus with the relocation of the Jean Porter apheresis 
unit and many of the professional nurses it has been pos-
sible to continue reporting consecutive recipients to the 
Center for International Bone Marrow Transplantation 
Research. This has ensured that their scheduled audits 
continue with accreditation: a status, which has re-
mained intact for more than three decades. 
Using this database the paediatric results could be 
compared to earlier experience from the State Hospital 
and document, apart from a more active private pro-
gram, essentially the same results.47 
The parallel experience in our adult cohort supports 
five conclusions.
Firstly, given a suitable physical facility and adher-
ence to management protocols that are commensurate 
with international standards of care, an environment 
could be created to meet and then sustain established 
criteria for international standard of care whilst con-
tinuing to develop and introduce new research top-
ics as appropriate. The cardinal consideration was a 
focus on the all-important haematology co-ordina-
tor managing a multidisciplinary management team 
made up of long stay nursing and paramedical pro-
fessionals including academic dieticians and skilled 
janitorial support staff with constant interaction be-
tween infectious disease, cardiology, nephrology and 
gastroeinterology consultants. Such a comprehensive 
unit emerges as the indispensable key to provision of 
unquestionably costly, albeit sophisticated, interven-
tions with the all-important appreciation that this is 
an entirely realistic undertaking even in an under-re-
sourced area of the globe.
Secondly, under these circumstances, outcome 
analysis is seen to approximate that from recognized 
reference centers in the field. This applies in the first 
three months with mortality largely related to the 
procedure itself. Then also, and of note, given the va-
garies of southern Africa with migrant populations 
and civil unrest, the opportunity of serially observing 
these individuals for more than 35 years to provide a 
reliable long term reference point for overall cost ef-
fectiveness. 
Thirdly in the specific context of ex vivo T-cell deple-
tion is the seminal observation that survival curves are 
stable and do not have late and previously unrecognised 
sequelae that differ from those generated in recipients 
exposed to conventionally used post - transplant im-
munosuppressive regimens. Thus there is no apparent 
impact of this unique immunosuppressive regimen on 
developing myelodysplasia or predisposing to chronic 
infections such as pulmonary tuberculosis so rampant 
in sub-Saharan Africa. It remains to be determined 
whether the slightly higher incidence of cytomegalovi-
ral infections translates into any clinically important re-
quirements other than the need for prompt recognition 
and proactive antiviral therapy. It is also momentarily 
unclear as to whether the impact of retroviral infections 
can be altered in the face of appropriate combination 
active retroviral therapy and this is the subject of on-
going study.155 Currently the quality-of-life with the 
low incidence of graft versus host disease, in its various 
forms, is gratifying.
Fourthly veno-occlusive disease has not been seen 
despite the use of intravenous busulphan. Furthermore 
peripheral blood stem cell mobilisation with G-CSF 
has been efficient with only relatively minor side effects 
of backache and bone pain in some donors. No differ-
ence can be seen when bone marrow is compared to 
peripheral blood as source of the graft. Also, and of rel-
evance, is that no serious adverse reactions156 have thus 
far been noted in donors despite which informed con-
sent has been altered to include extended surveillance 
both among siblings and matched unrelated volunteers 
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through each referring registry.43,157
Fifthly, immunohaematopoietic stem cell grafting 
including collaboration on a worldwide basis is entirely 
realistic in this country given that donations can be 
imported or exported with due observance to rules on 
moving human tissue between countries.43,158 This, in 
turn, is relevant and underlines the importance of our 
having established the South African Bone Marrow 
Registry43 that functions interchangeably with others 
throughout the world including in the United Kingdom, 
Europe159 and the American National Marrow Donor 
Program.160 Logically such a network can provide an 
impartial repository to monitor country-wide activity 
with the further attraction of a database upon which to 
plan national protocols, co-operative clinical trials and 
research studies.
Conclusion
These procedures carried out in a properly constituted 
and dedicated unit continues to generate results that 
are comparable to those from established first world 
reference centers. The low transplant related mortal-
ity, rejection rate and graft-versus-host disease, previ-
ously reported are confirmed. The benefits of what is 
clearly a center effect cannot necessarily be extrapo-
lated to similar interventions performed outside des-
ignated and monitored academically orientated facili-
ties. In Third World countries, given current parlous 
financial climate and rampant retroviral epidemics, 
allocation of restricted resources for this purpose is 
rationally most sensible when limited to established, 
audited and accredited teams. Such a stance rests 
heavily on publication of outcome to justify ongoing 
support. It will also direct focus to actual achievement 
in contrast to the currently favoured incentive-driven 
preferred providers.
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